nach oben

European Archives of Oto-Rhino-Laryngology

Erschienen in:

10.10.2019 | Head and Neck

Disease course after the first recurrence of head and neck squamous cell carcinoma following (chemo)radiation

verfasst von: Mischa de Ridder, Pieter D. de Veij Mestdagh, Joris B. W. Elbers, Arash Navran, Charlotte L. Zuur, Ludi E. Smeele, Abrahim Al-Mamgani

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Recurrent head and neck squamous cell carcinoma (HNSCC) after chemoradiation is a challenging clinical problem. Salvage surgery (SS) is often extensive and mutilating. Oncological outcomes of SS are relatively well known, but little is published about the course of disease after the first recurrence, especially in patients without salvage possibilities. The aim of this study was to analyze the course of disease in patients with recurrent HNSCC after chemoradiation.

Methods

We retrospectively analyzed and descriptively reported the disease course in 198 patients with recurrent HNSCC after chemoradiation in the time period after the first recurrence. We scored any type of event, salvage treatment, systemic treatment and overall survival (OS).

Results

Of the 198 patients with recurrent HNSCC, salvage surgery was attempted in 104 (53%). SS was more frequently given in patients with recurrent laryngeal cancer, isolated regional failure (p < 0.001) and HPV-positive disease (p = 0.09). The 2-year OS of the whole group was 31% and was significantly different by tumor site, type of failure and SS. HPV-positive disease and salvaged recurrences were significantly predictive for better survival. One third of that salvaged patients was still alive without second recurrence. Median survival in patients that received any palliative systemic treatment without surgery, compared to those were no treatment was given, was 6 and 3 months, respectively (p = 0.006).

Conclusions

Main factors influencing the course of disease in recurrent HNSCC are the possibilities for SS and HPV-status. Therefore, SS should always be considered and discussed. In patients without possibilities for SS, overall survival is 3–6 months.

Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS (2013) Long-term results of RTOG 91–11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31(7):845–852. https://doi.org/10.1200/JCO.2012.43.6097 CrossRefPubMed

Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21–28. https://doi.org/10.1016/S1470-2045(09)70311-0 CrossRefPubMed

Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14. https://doi.org/10.1016/j.radonc.2009.04.014 CrossRef

Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, Rosen FR, Jovanovic B, Vokes EE (2004) Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 10(6):1956–1962CrossRef

De Felice F, Thomas C, Barrington S, Pathmanathan A, Lei M, Urbano TG (2015) Analysis of loco-regional failures in head and neck cancer after radical radiation therapy. Oral Oncol 51(11):1051–1055. https://doi.org/10.1016/j.oraloncology.2015.08.004 CrossRefPubMed

Caudell JJ, Meredith RF, Spencer SA, Keene KS, Dobelbower MC, Bonner JA (2010) Margin on gross tumor volume and risk of local recurrence in head-and-neck cancer. Int J Radiat Oncol Biol Phys 76(1):164–168. https://doi.org/10.1016/j.ijrobp.2009.01.037 CrossRefPubMed

de Ridder M, Gouw ZAR, Sonke JJ, Navran A, Jasperse B, Heukelom J, Tesselaar MET, Klop WMC, van den Brekel MWM, Al-Mamgani A (2017) Recurrent oropharyngeal cancer after organ preserving treatment: pattern of failure and survival. Eur Arch Otorhinolaryngol 274(3):1691–1700. https://doi.org/10.1007/s00405-016-4413-7 CrossRefPubMed

Dandekar V, Morgan T, Turian J, Fidler MJ, Showel J, Nielsen T, Coleman J, Diaz A, Sher DJ (2014) Patterns-of-failure after helical tomotherapy-based chemoradiotherapy for head and neck cancer: implications for CTV margin, elective nodal dose and bilateral parotid sparing. Oral Oncol 50(5):520–526. https://doi.org/10.1016/j.oraloncology.2014.02.009 CrossRefPubMed

Daly ME, Le QT, Maxim PG, Loo BW Jr, Kaplan MJ, Fischbein NJ, Pinto H, Chang DT (2010) Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 76(5):1339–1346. https://doi.org/10.1016/j.ijrobp.2009.04.006 CrossRefPubMed

10.

Mendenhall WM, Mendenhall CM, Malyapa RS, Palta JR, Mendenhall NP (2008) Re-irradiation of head and neck carcinoma. Am J Clin Oncol 31(4):393–398. https://doi.org/10.1097/COC.0b013e3181637398 CrossRefPubMed

11.

Guo T, Qualliotine JR, Ha PK, Califano JA, Kim Y, Saunders JR, Blanco RG, D'Souza G, Zhang Z, Chung CH, Kiess A, Gourin CG, Koch W, Richmon JD, Agrawal N, Eisele DW, Fakhry C (2015) Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer. Cancer 121(12):1977–1984. https://doi.org/10.1002/cncr.29323 CrossRefPubMedPubMedCentral

12.

Sanabria A, Silver CE, Olsen KD, Medina JE, Hamoir M, Paleri V, Mondin V, Rinaldo A, Rodrigo JP, Suarez C, Boedeker CC, Hinni ML, Kowalski LP, Teymoortash A, Werner JA, Takes RP, Ferlito A (2014) Is elective neck dissection indicated during salvage surgery for head and neck squamous cell carcinoma? Eur Arch Otorhinolaryngol 271(12):3111–3119. https://doi.org/10.1007/s00405-014-2893-x CrossRefPubMed

13.

Hamoir M, Holvoet E, Ambroise J, Lengele B, Schmitz S (2017) Salvage surgery in recurrent head and neck squamous cell carcinoma: oncologic outcome and predictors of disease free survival. Oral Oncol 67:1–9. https://doi.org/10.1016/j.oraloncology.2017.01.008 CrossRefPubMed

14.

Goodwin WJ Jr (2000) Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 110(3 Pt 2 Suppl 93):1–18. https://doi.org/10.1097/00005537-200003001-00001 CrossRefPubMed

15.

Zafereo ME, Hanasono MM, Rosenthal DI, Sturgis EM, Lewin JS, Roberts DB, Weber RS (2009) The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer 115(24):5723–5733. https://doi.org/10.1002/cncr.24595 CrossRefPubMed

16.

Leeman JE, Li JG, Pei X, Venigalla P, Zumsteg ZS, Katsoulakis E, Lupovitch E, McBride SM, Tsai CJ, Boyle JO, Roman BR, Morris LGT, Dunn LA, Sherman EJ, Lee NY, Riaz N (2017) Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques. JAMA Oncol 3(11):1487–1494. https://doi.org/10.1001/jamaoncol.2017.0973 CrossRefPubMedPubMedCentral

17.

Elbers JBW, Veldhuis LI, Bhairosing PA, Smeele LE, Jozwiak K, van den Brekel MWM, Verheij M, Al-Mamgani A, Zuur CL (2019) Salvage surgery for advanced stage head and neck squamous cell carcinoma following radiotherapy or chemoradiation. Eur Arch Otorhinolaryngol. https://doi.org/10.1007/s00405-019-05292-0 CrossRefPubMed

18.

Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35. https://doi.org/10.1056/NEJMoa0912217 CrossRefPubMedPubMedCentral

19.

Huang SH, Perez-Ordonez B, Weinreb I, Hope A, Massey C, Waldron JN, Kim J, Bayley AJ, Cummings B, Cho BC, Ringash J, Dawson LA, Siu LL, Chen E, Irish J, Gullane P, Hui A, Liu FF, Shen X, Xu W, O'Sullivan B (2013) Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol 49(1):79–85. https://doi.org/10.1016/j.oraloncology.2012.07.015 CrossRefPubMed

20.

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116–1127. https://doi.org/10.1056/NEJMoa0802656 CrossRefPubMed

21.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML (2018) Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 81:45–51. https://doi.org/10.1016/j.oraloncology.2018.04.008 CrossRefPubMedPubMedCentral

22.

Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, Rotman M, Meredith R (2001) RTOG 96–10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 51(5):1299–1304CrossRef

23.

Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, Wong S, Ang K (2007) Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of radiation therapy oncology group protocol 9911. J Clin Oncol 25(30):4800–4805. https://doi.org/10.1200/JCO.2006.07.9194 CrossRefPubMed

24.

Ho JC, Phan J (2018) Reirradiation of head and neck cancer using modern highly conformal techniques. Head Neck 40(9):2078–2093. https://doi.org/10.1002/hed.25180 CrossRefPubMed

25.

Romesser PB, Cahlon O, Scher ED, Hug EB, Sine K, DeSelm C, Fox JL, Mah D, Garg MK, Han-Chih Chang J, Lee NY (2016) Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. Int J Radiat Oncol Biol Phys 95(1):386–395. https://doi.org/10.1016/j.ijrobp.2016.02.036 CrossRefPubMedPubMedCentral

26.

Ward MC, Riaz N, Caudell JJ, Dunlap NE, Isrow D, Zakem SJ, Dault J, Awan MJ, Vargo JA, Heron DE, Higgins KA, Beitler JJ, Marcrom S, Boggs DH, Hassanzadeh C, Reddy CA, Bonner JA, Yao M, Machtay M, Siddiqui F, Trotti AM, Lee NY, Koyfman SA, Multi-Institution Reirradiation C (2018) Refining patient selection for reirradiation of head and neck squamous carcinoma in the IMRT Era: a multi-institution cohort study by the MIRI collaborative. Int J Radiat Oncol Biol Phys 100(3):586–594. https://doi.org/10.1016/j.ijrobp.2017.06.012 CrossRefPubMed

Titel: Disease course after the first recurrence of head and neck squamous cell carcinoma following (chemo)radiation
verfasst von: Mischa de Ridder
Pieter D. de Veij Mestdagh
Joris B. W. Elbers
Arash Navran
Charlotte L. Zuur
Ludi E. Smeele
Abrahim Al-Mamgani
Publikationsdatum: 10.10.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Oto-Rhino-Laryngology / Ausgabe 1/2020
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-019-05676-2

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Disease course after the first recurrence of head and neck squamous cell carcinoma following (chemo)radiation